| 106 | x x

The successful use of mono-clonal antibodies (mAb) in the treatment of human disease has steadily been growing the last decade. Rituximab, a human-mouse chimeric anti-CD20 anti-body, was the first mAb for anti-lymphoma therapy approved. It was introduced as monotherapy and is now commonly used in combination with chemotherapy for first and subsequent lines of therapy in follicular non-Hodgkin lymphoma (FL) and chronic lym-phocytic leukemia (CLL)